French court orders Sanofi to compensate for Autistic Epileptic family

French court orders Sanofi to compensate for Autistic Epileptic family

PARIS Reuters - A French court ordered Sanofi to pay more than 400,000 euros $416,440 in damages to a family with a form of autism caused by its epilepsy drug Valproate, saying the drugmaker didn't inform about known side effects.

The class action ruling in January, which could potentially lead to hundreds of millions of euro in compensation, but Sanofi said it would file an appeal.

The latest ruling, made last week and seen by Reuters on Saturday, states that Sanofi must have known the risk that the drug, if taken by pregnant women, could cause neuro-behavioural disorders and malformations in children, which should have been mentioned in its attached leaflet.

Sanofi said in a statement it would appeal the decision, adding that the drug's risk-benefit ratio is positive.

The court in Nanterre ordered the company to compensate the parents of the girl for the various physical and psychological damages suffered, and resulting costs, such as special care and schooling needs.

The verdict is the first in France to state a link between Valproate, sold under the name Depakine in France, and disorders commonly referred to as autism in an individual case, said Marine Martin, who heads victim association APESAC.

I hope Sanofi will change its position and start compensating the victims now that more and more court decisions are being made by Martin, the mother of a child suffering from Depakine side effects, told Reuters on Saturday.

French health authorities said the drug was responsible for deformities between 2,150 and 4,100 children and neurodevelopmental defects in up to 30,400.

Sanofi was placed under formal investigation in 2020 on charges of manslaughter, but rebutted those charges at the time and said it would challenge the merits of the investigation.